玻璃体腔注射贝伐单抗Avastin后糖尿病视网膜患者血清中VEGF含量的变化研究

目的研究玻璃体腔注射贝伐单抗Avastin后增生性糖尿病视网膜病变（PDR）患者血清中血管内皮细胞生长因子（VEGF）的变化。方法收集玻璃体腔注射Avastin后PDR患者血清样本（注射前当天,注射后1 d,注射后7 d,注射后28 d）,并以注射前当天的血清样本为基准值作为对照,用ELISA方法测定血清中VEGF的含量。结果玻璃体腔注射Avastin术后,所有样本血清中VEGF含量都降低,降低幅度在术后7 d达到最大峰值,术后28 d VEGF有所上升,但仍未达到术前水平。结论一次玻璃体腔注射Avastin术后,血清中VEGF含量降低并且维持相当时间,说明Avastin进入到血液循环中,因此有必要密切关注Avastin玻璃体腔注射后的系统性影响和对未注射眼的影响。

Serum concentration of vascular endothelial growth factor after intravitreal administration of bevacizumab in patients with diabetic retinopathy

Objective Avastin（ bevacizumab） intravitreal injections are widely used in the treatment of diabetic retinopathy. This study was to determine the serum concentrations of vascular endothelial growth factor（ VEGF） in patients with diabetic retinopathy after intravitreal injection of bevacizumab. Methods Twenty-two patients（ 22 eyes） diagnosed with active proliferative diabetic retinopathy were enrolled in this study. Bevacizumab 1. 25 mg was administered intravitrealy. Serum VEGF concentration was measured by ELISA on the day of the bevacizumab administration and on day 1,day7,and day 28. Results Twenty-four hours after bevacizumab administration,serum VEGF concentration significantly decreased from baseline in all patients,and reached a nadir at the 7th day. VEGF level rose again at 28 days after the treatment but did not reached pre-treatment level in most of patients. Conclusion Decreased serum VEGF level after single intravitreal injection of bevacizumab indicated that bevacizumab entered the circulation and maintained a therapeutic level for a long time. Therefore,physicians should be cautious about systemic side effects and side effects in the fellow eye.